Video

Dr. Kutikov discusses recent NCCN guideline reversal on active surveillance

Author(s):

Urology Times staff

In this video, Alexander Kutikov, MD, FACS, discusses the recent National Comprehensive Cancer Network guideline reversal regarding active surveillance in men with low-risk prostate cancer. Kutikov is the chief of the division of urology and urologic oncology, professor in the department of surgical oncology, and the Roberta R. Scheller Chair in urologic oncology at the Fox Chase Cancer Center at Temple University in Philadelphia, Pennsylvania.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Michael Jenson, PA-C, answers a question during a Zoom video interview
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
Related Content
Targeted microwave ablation shows precision, safety in localized prostate cancer
November 21st 2024

Targeted microwave ablation shows precision, safety in localized prostate cancer

Hannah Clarke
In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Study indicates overtreatment of men with prostate cancer and limited life expectancy
November 20th 2024

Study indicates overtreatment of men with prostate cancer and limited life expectancy

Hannah Clarke
“Prostate cancer patients with life expectancies of less than 5 or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, despite guidelines recommending against treatment," says Timothy J. Daskivich, MD.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Study characterizes long-term impact of prostate cancer treatment
November 8th 2024

Study characterizes long-term impact of prostate cancer treatment

Hannah Clarke
“Our study is distinguished by long follow-up, out to 12 years, looking at a broad spectrum of key complications," says Joseph M. Unger, PhD.
Phase 1/2 trial of ONCT-534 in mCRPC has been terminated
November 7th 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated

Hannah Clarke
The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.
© 2024 MJH Life Sciences

All rights reserved.